## Abstract ## BACKGROUND In the National Surgical Adjuvant Breast and Bowel Project (NSABP) Pβ1 trial, tamoxifen was shown to reduce breast carcinoma risk by 49% in highβrisk women. The purpose of the current study was to identify factors associated with being offered, and accepting, tamoxifen ch
β¦ LIBER β¦
Acceptance of tamoxifen chemoprevention by physicians and women at risk
β Scribed by Andrew McKay; Steve Latosinsky; Wanda Martin
- Book ID
- 102105464
- Publisher
- John Wiley and Sons
- Year
- 2004
- Tongue
- English
- Weight
- 57 KB
- Volume
- 103
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Acceptance of tamoxifen chemoprevention
β
Julia Tchou; Nanjiang Hou; Alfred Rademaker; V. Craig Jordan; Monica Morrow
π
Article
π
2004
π
John Wiley and Sons
π
English
β 79 KB
Chemoprevention of breast cancer by tamo
β
Lewis L. Smith; Ian N.H. White
π
Article
π
1995
π
Elsevier Science
π
English
β 583 KB
PCN1 LONG-TERM BENEFITS OF CHEMOPREVENTI
β
R Borker; S Madhavan; K Simon; G Higa; M Amonkar; V Scott
π
Article
π
2002
π
John Wiley and Sons
π
English
β 80 KB
Acceptability and Adherence in a Chemopr
β
Razzaboni, Elisabetta; Toss, Angela; Cortesi, Laura; Marchi, Isabella; Sebastian
π
Article
π
2012
π
John Wiley and Sons
π
English
β 218 KB
Frequency of nursing, physician, and hos
β
John Morrison; William Roberts; Gary Stanziano
π
Article
π
2003
π
Lippincott Williams and Wilkins
π
English
β 57 KB
Identification of a chemoprevention coho
Identification of a chemoprevention cohort from a population of women at high risk for breast cancer
β
Carol J. Fabian; Sahar Kamel; Carola Zalles; Bruce F. Kimler
π
Article
π
1996
π
John Wiley and Sons
π
English
β 935 KB
In a prospective pilot study, we performed breast fine needle aspirations (FNAs) on 21 3 high-risk and 30 low-risk women and analyzed these aspirates for cytologic changes and biomarker abnormalities of aneuploidy and overexpressed estrogen receptor (ER), epidermal growth factor receptor (ECFR), p53